Furthermore, EPHA10 has already been approved as a potential therapeutic target of prostate cancer (Nagano et al., 2014), and high EPHA10 expression correlated with lymph node metastasis of breast cancer (Nagano et al., 2013)—the type of malignant behavior that usually predicts a poor prognosis. Here, EPHA10 is linked to breast carcinoma.